There are two other issues. Intravenous ketamine brings very short-lived effects. The effects described above are very brief and the patient is kept safe during that time. About twenty minutes to half an hour in total. This is the antithesis of being drugged around the clock. The other thing is that brief periods involving just a few sessions do not cause the damaging effects that regular, long-term applications of the patented products do. When actual Ketamine was found to be beneficial for some people experiencing long-term and intractable despair, there came a plethora of attempts to create a patentable, commercial product. Ketamine itself has been off-patent for decades. In order to patent an off-patent drug, it needs to be altered in some way. It seems likely that the ‘need’ for a commercial product may mean the resulting commodity is less effective. It may also, potentially, be dangerous. Off-patent Ketamine has been safely studied and used in controlled settings and for a variety of conditions, for a very long time.